Dual-targeting radiopharmaceutical therapy safe and effective across multiple cancers

A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown to be safe and effective in human trials. Acting like a “smart missile,” the dual-targeting radiopharmaceutical is designed to attach to two vulnerable sites on cancer cells, enabling more precise and potent therapy. Early results show that nearly 90% of patients experienced either tumor shrinkage or disease stabilization. These findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.
Read More

Targeting fusion protein’s role in childhood leukemia produces striking results

Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.
Read More

Cancer before 40: Eexpert shares 3 topics that younger patients often want to discuss

Dr. Allison Rosenthal’s experience facing a leukemia diagnosis while in medical school inspired her to pursue a career fighting cancer. It also gave her insight into aspects of life with cancer for people under 40. Now, Dr. Rosenthal is among the leaders of an effort at Mayo Clinic Comprehensive Cancer Center to help younger adults and older teens receive age-appropriate care and support. In this expert alert, Dr. Rosenthal shares three topics that younger people with cancer often want to discuss with their healthcare teams.
Read More
Top